TriSalus Life Sciences (TLSI) Liabilities and Shareholders Equity (2020 - 2026)

TriSalus Life Sciences (TLSI) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $71.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 147.96% year-over-year to $71.0 million; the trailing twelve-month figure through Mar 2026 stood at $184.1 million (up 63.63% YoY), and the FY2025 full-year result was $35.3 million, up 47.39% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $71.0 million, up from $35.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $251.3 million in Q3 2022 and bottomed at $12.2 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $32.4 million (2024), against an average of $69.4 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity slumped 95.12%; it then jumped 165.01% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $22.0 million in 2022, then increased by 11.83% to $24.6 million in 2023, then fell by 2.55% to $24.0 million in 2024, then soared by 47.39% to $35.3 million in 2025, then jumped by 100.9% to $71.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $71.0 million (Q1 2026), $35.3 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.

Peer Comparison